Study guide
7.3 Rh Phenotyping and Clinical Significance
Scientist in Blood Banking, BB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes and Application 1.3 CMP, Credential Citation, and BB vs SBB
2 Donors and Collection
2.1 Donor Qualification 2.2 Collection Methods and Adverse Reactions 2.3 Special Donations
3 Processing, Storage, and Component QC
3.1 Processing: FDA/AABB Requirements, Testing, and Labeling 3.2 Anticoagulants, Additives, and Storage Temperatures 3.3 Transportation, Stored-Product Properties, and Expiration 3.4 Blood Component Quality Control
4 Blood Components
4.1 Red Blood Cells, Whole Blood, Washed, Frozen, and Rejuvenated 4.2 Platelets, Plasma, and Cryoprecipitated AHF 4.3 Granulocytes, Leukoreduced, and Irradiated Components 4.4 Apheresis Products, Fractionation, and Hematopoietic Progenitors
5 Blood Group Genetics and Transfusion Role
5.1 Basic and Molecular Genetics 5.2 Inheritance of Blood Groups 5.3 Immunogenicity and Antigen Prevalence
6 ABO and Lewis Systems
6.1 ABO Biochemistry and Antigens 6.2 ABO Antibodies, Discrepancies, and Subgroups 6.3 Lewis System
7 Rh System
7.1 Rh Genetics and Antigens 7.2 Weak D, Partial D, and Rh Antibodies 7.3 Rh Phenotyping and Clinical Significance
8 Kell, Duffy, Kidd, and MNS
8.1 Kell System 8.2 Duffy System 8.3 Kidd System 8.4 MNS System
9 Additional Systems and Antigens
9.1 P1PK, Globoside, and Ii Systems 9.2 Lutheran and Other Blood Group Systems 9.3 High- and Low-Prevalence Antigens 9.4 HLA, Platelet-Specific, and Granulocyte-Specific Antigens
10 Immunology Foundations
10.1 Immune Response, B and T Cells, Macrophages 10.2 Immunoglobulins: Classes, Structure, and Properties 10.3 Antigen-Antibody Interactions and Testing 10.4 Complement Pathways and Biologic Properties
11 Physiology, Hemostasis, Cytopenias, and Transplantation
11.1 Physiology of Blood 11.2 Hemostasis and Coagulation 11.3 Immune and Nonimmune Cytopenias 11.4 Solid Organ and HPC Transplantation
12 Hemolytic Disease of the Fetus and Newborn
12.1 HDFN Pathophysiology 12.2 HDFN Detection 12.3 HDFN Treatment and Prevention
13 Routine Serologic Testing
13.1 Blood Grouping Tests 13.2 Antibody Detection 13.3 Compatibility Testing and Crossmatch 13.4 Direct Antiglobulin Testing
14 Antibody Identification
14.1 Antibody Identification and Rule-Out 14.2 Clinical Significance, Dosage, and Multiple Antibodies 14.3 Panel Problem-Solving and Common Traps
15 Reagents and Special Techniques
15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells 15.2 Enzymes, Enhancement Media, and Lectins 15.3 Adsorption, Elution, Titration, and Cell Separations 15.4 Molecular, Solid-Phase, Column, ELISA, and Related Methods
16 Serologic QA and Special Reagents
16.1 Blood Sample Quality Assurance 16.2 Reagent and Procedure Quality Assurance 16.3 Thiol Reagents, Neutralization, Chloroquine, EGA, and Immunofluorescence
17 Indications and Component Therapy
17.1 Indications for Transfusion 17.2 Red Cell and Whole Blood Therapy 17.3 Platelet, Plasma, and Cryoprecipitate Therapy 17.4 Special Component Therapy
18 Adverse Effects of Transfusion
18.1 Immunologic Transfusion Reactions 18.2 Nonimmunologic Transfusion Reactions 18.3 Transfusion-Transmitted Diseases
19 Apheresis, Administration, and Patient Blood Management
19.1 Apheresis and Extracorporeal Circulation 19.2 Blood Administration 19.3 Patient Blood Management
20 Laboratory Operations
20.1 Quality Assessment and Troubleshooting 20.2 Quality Control, Proficiency Testing, and Regulation 20.3 Laboratory Safety 20.4 Laboratory Mathematics and Instrumentation
7.3 Rh Phenotyping and Clinical Significance
Key Takeaways Explain This Topic AI
Modern D reagents are IgM monoclonal or IgM/IgG blends. High-protein reagents need an Rh control; a positive control invalidates the D type.
Chronically transfused patients, especially with sickle cell disease, should receive C, c, E, e, and K matched red cells when feasible so they do not add Rh and Kell antibodies to the problem list.
Give D-neg red cells to D-neg women of childbearing potential. Platelets can carry residual red cells — prefer D-neg platelets or give RhIG after D+ platelets.
Anti-G is separated from anti-C+D by adsorption with r' (dCe) and R0 (Dce) cells. A D-neg pregnant patient who has anti-G but not anti-D still needs RhIG.
Unexpected anti-D in a D+ patient is partial D (or passive RhIG/IVIG) until proven otherwise. Mixed-field D after transfusion is not a new inherited type.
Last updated: August 2026
7.3 Rh Phenotyping and Clinical Significance
Quick Answer: Type D with IgM monoclonal or IgM/IgG blend reagents. High-protein anti-D can false-positive; you need an Rh control . Do not phenotype recently transfused patients and believe it. Chronically transfused patients, especially sickle cell , should get C, c, E, e, and K matched red cells when you can. RhIG indications start here; full dosing lives in the HDFN chapter. D-neg women of childbearing potential get D-neg RBC , and D-neg platelets when possible — platelets carry residual RBC , so give RhIG if a D+ platelet is issued. Exam classics: anti-G versus anti-C+D (adsorption) and unexpected anti-D in a D+ patient = partial D .
Section 7.1 gave you haplotypes. Section 7.2 gave you weak versus partial D. This section is the bench and the blood order. II.B.3 still owns it; transfusion-practice chapters will reuse every rule.
Reagents, controls, and who you must not type
Current D reagents are low-protein monoclonal IgM (immediate-spin direct agglutination) or IgM/IgG blends (IS plus the option to take the same tube to AHG for weak D). IgM clones differ in which partial D they see. That is a feature: patient reagents may miss DVI so the patient is managed as D-neg; donor reagents must detect DVI so the unit is labeled D+. Do not “fix” a DVI patient by switching to a donor clone and relabeling them D+.
High-protein anti-D — older human polyclonal reagents in albumin or other potentiators — can agglutinate DAT-positive cells even when D is absent. Those reagents require an Rh control : the same diluent without anti-D. A positive control invalidates the D type . Repeat with a low-protein monoclonal, wash the cells, check the DAT, and do not report D+ off a sticky high-protein tube. Run a control whenever the sample is DAT-positive , when the patient types AB, D+ with a reagent that needs it, or whenever the SOP says the diluent can cause spontaneous agglutination.
Recently transfused patients circulate donor red cells. A D type, and especially a C/c/E/e phenotype, can be mixed-field or frankly the donor’s type. Do not call a newly mixed-field D a genetic change. Use a pretransfusion type, reticulocyte separation if the SOP allows it, or molecular RH typing on white-cell or buccal DNA (Chapter 5). The same warning applies after HPC transplant : the forward type can migrate toward the donor over weeks.
C, c, E, and e reagents are monoclonal or polyclonal and are read by the manufacturer’s phase. Enzyme-treated cells type stronger for Rh and can help a weak e, but they also enhance cold autoantibodies — do not create an e+ you cannot defend.
D typing discrepancies you will be handed
Work them in this order:
Clerical and reagent. Wrong sample, expired clone, under-centrifuged tube.
Mixed field. Recent D+ or D− transfusion, fetomaternal bleed, transplant. History first.
Weak or discrepant D between two reagents. Partial D or weak D. Do not average the grades. Follow Section 7.2: protect as D-neg, genotype if the patient is a candidate.
DAT-positive / control-positive. Invalid D with high-protein or AHG reagents. Clean the cells or switch reagents.
Historical D+ now D−, or the reverse. Look for transplant, massive transfusion, or a prior mis-type on a partial D clone.
Do not report a D type you cannot defend, and do not issue D+ red cells to a woman of childbearing potential while the discrepancy is open.
Who gets phenotype-matched blood
Chronically transfused patients, especially sickle cell disease and to a lesser extent thalassemia , form Rh and Kell antibodies at a rate that wrecks later support. Standard U.S. practice is to issue red cells matched at least for C, c, E, e, and K (and ABO/D, obviously). Many programs add Duffy, Kidd, and S once an antibody appears, or up front if a genotype is already on file. African-ancestry patients are enriched for partial D, partial C, and partial e ; a serologic match can still allow alloanti-D or alloanti-e. When the antibody ID looks like anti-e in an e+ sickle-cell patient, think partial e and send RHCE genotyping , do not just call it warm auto and give least-incompatible e+ units forever.
Extended matching is not required for a one-time orthopedic transfusion in a patient with a negative antibody screen. Do not spend C−E−K− units on that case; those units belong to the sickle-cell service.
RhIG preview — indications, not the full dose math
Rh immune globulin prevents anti-D formation in a D-neg person exposed to D+ red cells . Classic obstetric indications, with dosing reserved for the HDFN chapter:
Antepartum , about 28 weeks , when the mother is D-neg and has not already made immune anti-D.
Postpartum , within 72 hours , if the infant is D+ or weak D+ .
After miscarriage, abortion, ectopic, amniocentesis, CVS, version, abdominal trauma, or stillbirth when the fetus could be D+.
RhIG is not indicated if the mother already has immune anti-D . It is still indicated if she has anti-C, anti-E, or anti-G without anti-D — those antibodies do not protect her from making anti-D. Antepartum RhIG will make the antibody screen positive; that passive anti-D is not a reason to skip the postpartum dose when the infant is D+. Full vial math, Kleihauer–Betke, and rosette testing belong in the HDFN chapter. Here you only need the trigger list and the anti-G exception.
Women of childbearing potential, red cells, and platelets
A D-neg woman who can still become pregnant receives D-neg red cells unless a massive-bleeding protocol has emptied that inventory and the medical director has accepted the immunization risk. The same woman should receive D-neg platelets when possible . Platelet units are not “red-cell free.” Apheresis and whole-blood platelets contain residual erythrocytes , enough to immunize. If a D+ platelet must be issued, give RhIG . One standard 300 µg vial covers far more red-cell volume than a platelet dose contains; you do not need a Kleihauer after a platelet. D-neg men and D-neg women who are not of childbearing potential may receive D+ platelets without RhIG when inventory demands it — local policy decides, but the exam’s protected person is the woman who can still carry a D+ fetus.
Plasma and cryoprecipitate do not carry a meaningful D-immunization risk. Do not waste RhIG on AB plasma.
Exam scenario: anti-G versus anti-C+D
A D-neg, C-neg patient (usually rr) has a serum that reacts with every C+ or D+ cell and misses rr cells. That pattern is anti-C+D, anti-G, anti-C+G, anti-D+G, or the full trio . You cannot tell from the panel alone.
Adsorption geometry uses the two cells that carry G with only one of the major antigens:
- Adsorbing cell Antigens Removes Leaves behind
- r' (dCe) C+ G+ D− anti-C and anti-G anti-D
- R0 (Dce) D+ G+ C− anti-D and anti-G anti-C
If r' cells remove all activity, there was no anti-D — the serum was anti-G ± anti-C. If activity remains after r' adsorption and that leftover reacts with D+ C− cells, anti-D is present . Repeat the logic with R0 cells to ask whether anti-C exists. Eluates off each adsorbing cell confirm what bound.
Why the BB exam cares: a prenatal patient with anti-G but not anti-D still needs RhIG and still needs the infant monitored, but the antibody you are titering for D-HDFN risk is not there. Treat her as if she had anti-C+D and you will skip RhIG and mis-counsel. Treat every G pattern as “she already has anti-D” and you make the same mistake.
Exam scenario: unexpected anti-D in a D+ person
A patient types D+ (sometimes weak, sometimes 3+) and the antibody ID is anti-D . Autocontrol may be negative. This is alloanti-D in a partial D until you prove otherwise. Manage as D-neg for red cells, offer RhIG if she is pregnant and the anti-D could still be passive, and send RHD genotyping . Differential to keep honest:
Passive anti-D from recent RhIG or IVIG — history, low titer, declining.
Autoanti-D — positive autocontrol / DAT, panagglutinin after warm autoadsorption may remain D-like.
Anti-LW — can mimic anti-D; DTT-treated or cord-cell patterns differ; rare on BB stems.
Do not “correct” the D type to negative on paper and forget to tell the transfusion service. Do not issue D+ units because the analyzer printed D+.
Exam traps
Reporting D+ off a positive Rh control .
Phenotyping a patient who was transfused yesterday and treating the mixed field as genotype.
Matching only D and K in a sickle-cell program and ignoring C, c, E, e .
Withholding RhIG because anti-G “already covers D.”
Giving D+ platelets to a D-neg woman of childbearing potential without RhIG.
Calling unexpected anti-D in a D+ patient an autoantibody without considering partial D .